Literature DB >> 8735545

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies.

P H Ibsen1.   

Abstract

The effect of detoxification of pertussis toxin (PT) for vaccine usage by either genetic manipulation, hydrogen peroxide or formaldehyde treatment on epitope recognition by a large collection of murine monoclonal pertussis toxin antibodies (PT MAbs) was assessed in a solid-phase and a soluble phase enzyme-linked immunosorbent assay (ELISA). The MAb binding patterns were found to be different in the two assays as the immobilization step appeared to cause conformational alterations in the native as well as the toxoided forms of PT. According to the solid-phase ELISA, genetic, hydrogen peroxide and 0.35% formaldehyde detoxification of PT resulted in reduced epitope binding in 2.9, 31.4 and 78.1% of the MAbs, respectively. In the soluble-phase ELISA, in which the MAbs were allowed to react with the toxoids or native toxin in solution, the percentages of MAbs showing decreased binding activity were 9.1, 50.0 and 71.4%, respectively. Stabilization of native PT and the genetically inactivated PT by 0.035% formaldehyde reduced the epitope binding activity in 50.0 and 8.7% of the MAbs, respectively. Increased antibody binding in the soluble-phase ELISA was observed in some of the toxoids: this ranged from 0% in the 0.35% formaldehyde-treated PT to 13.6% in the hydrogen peroxide-treated and 27.3% in the genetically detoxified PT. Regarding the effects of detoxification on epitopes recognized by PT-neutralizing MAbs in the soluble-phase ELISA, we found that treatment of PT with either 0.035%, 0.35% formaldehyde or hydrogen peroxide induced impairment of epitope binding in 72.7, 81.8 and 45.5% of the MAbs, respectively. In the genetically inactivated PT, the epitopes recognized by the neutralizing MAbs either appeared to remain intact or to show increased MAb binding activity. The epitope-binding patterns of several PT MAbs with mouse-protective properties varied considerably and were shown to be dependent on the detoxification procedure employed. The relevance of epitope alterations on PT as a vaccine component is discussed. The results of the present study may have important implications for future quality assessment of PT for use in acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735545     DOI: 10.1016/0264-410x(95)00230-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.

Authors:  Jamie N Sutherland; Christine Chang; Sandra M Yoder; Michael T Rock; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

Review 2.  What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.

Authors:  Dimitri A Diavatopoulos; Kathryn Margaret Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

3.  Confocal microscopy study of pertussis toxin and toxoids on CHO-cells.

Authors:  Yajun Tan; Roland A Fleck; Catpagavalli Asokanathan; Chun-Ting Yuen; Dorothy Xing; Shumin Zhang; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 4.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

5.  Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.

Authors:  Ke Jin; Shixia Wang; Chunhua Zhang; Yanling Xiao; Shan Lu; Zuhu Huang
Journal:  Hum Vaccin Immunother       Date:  2012-11-10       Impact factor: 3.452

6.  Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine.

Authors:  Masaki Ochiai; Yoshinobu Horiuchi; Chun-Ting Yuen; Catpagavalli Asokanathan; Akihiko Yamamoto; Kenji Okada; Michiyo Kataoka; Kevin Markey; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 8.  What Is Wrong with Pertussis Vaccine Immunity? Inducing and Recalling Vaccine-Specific Immunity.

Authors:  Christiane S Eberhardt; Claire-Anne Siegrist
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

9.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

Review 10.  Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  F Heath Damron; Mariette Barbier; Purnima Dubey; Kathryn M Edwards; Xin-Xing Gu; Nicola P Klein; Kristina Lu; Kingston H G Mills; Marcela F Pasetti; Robert C Read; Pejman Rohani; Peter Sebo; Eric T Harvill
Journal:  J Immunol       Date:  2020-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.